- Email: [email protected]
NATO Advanced Study Institute Radiolabeled Monoclonal Antibodies for Imaging and Therapy Potential, Problems, and Prospects
Nucl. Med. Biol. Vol.13, No. 6, pp. 647-613 ht. .I. Radiat. Appl. Instrum. Part B
Pergamon Journals Ltd.Printed inGreatBritain
NAl'OADVANCEDSTDDYIXSTITtllZ RADIOLAB~DIIONOUONAL ANTIBODIES FOR IMAGING AND THERAPY Potential, Problems, and Prospects July 20 - August 1; 1986 Castelvecchio Pascoli, Italy
The NATO Advanced Study Institute (ASI) on 11 Radiolabeled Monoclonal Antibodies for Imaging and Therapy - Potential, Problems, and Prospects," was held July 20 - August 1, 1986 at the 11 Ciocco International Center, Castelvecchio Pascoli, Italy. In addition to the principal sponsorship by the North Atlantic Treaty Organization, the AS1 was co-sponsored by the United States Department of Energy, Office of Health and Environmental Research. Partial financial support was also provided by the following: Abbott Laboratories. USA; Bristol-Meyers Company, USA; Capintec, Inc., Dow USA; Compagnie Oris Industrie, France; Cytogen Corporation, USA; Organon Teknika, NV, Chemical Company, USA; Medi-Physics, Inc., USA; Belgium; Siemens Gammasonics, Inc., USA; and Sorin Biomedica, Italy. Approximately 110 participants representing about fifteen countries attended this two-week meeting. The main objective of this AS1 was to present a comprehensive program of lectures and presentations in the exciting and relatively new area of radiolabeled monoclonal antibodies. The topics that were covered in depth include: 1) Immunochemistry of hybridomas, and the production, purification, and fragmentation of monoclonal antibodies; 2) Production and the chemistry of radionuclides; 3) Radiohalogenation and radiometal labeling techniques; 4) Specificity, affinity, and immunoreactivity considerations; 5) In-vivo pharmacokinetics and other selection criteria; 6) Radiobiology and radiation dosimetry; 7) Optimum instrumentation and imaging techniques; 8) In-vivo radioimmunoscintigraphyand radioimmunotherapyresults; 9) Clinical studies and experience; and 10) Perspectives and directions for future research. Two workshops on "Methods for Determining Immunoreactivity of Radiolabeled Monoclonal Antibodies - Problems and Pitfalls," and "Radiobiological and Dosimetric Considerations for Immunotherapy with Labeled Antibodies" were also scheduled. There were a total of forty-three tutorial and focused scientific presentations (including the latest research data). In addition to these, eight short oral presentations and six poster presentations were included. Each presentation was followed by extensive discussion periods. The unique NATO AS1 format provided ample opportunities for extensive formal and informal interactions and scientific exchanges among the participants. The abstracts are compiled in the order of their presentation. For the short oral and the poster presentations, only the titles and author names appear. The proceedings of this meeting will be published in's hard-cover book format (NATO AS1 Series: A: Life Sciences) by the Plenum Publishing Corporation, 233 Spring Street. New York, N.Y. 10013, during Spring, 1987. Suresh C. Srivastava NATO AS1 Director
RAD10IMMUNOTHEgAP YOFGANGER: HISTOEIGAL PERSPECTIVES AND PRoSPECl'SFOR THE FUTURE. William H. Beierwaltes. University of Michigan, Ann Arbor, Michigan, USA. Our cure of a patient with advanced malignant melanoma 12/7/51 (U Mich Med Bull 20: 284, 1956) with 27 mCi of I-131 tagged to 90 mg of gamma globulin from rabbits immunized with the patient's own whole live cancer cells furnished encouragement to spend the next 35 years trying to furnish an explanation for the cure. 647
Pergamon Journals Ltd.Printed inGreatBritain
NAl'OADVANCEDSTDDYIXSTITtllZ RADIOLAB~DIIONOUONAL ANTIBODIES FOR IMAGING AND THERAPY Potential, Problems, and Prospects July 20 - August 1; 1986 Castelvecchio Pascoli, Italy
The NATO Advanced Study Institute (ASI) on 11 Radiolabeled Monoclonal Antibodies for Imaging and Therapy - Potential, Problems, and Prospects," was held July 20 - August 1, 1986 at the 11 Ciocco International Center, Castelvecchio Pascoli, Italy. In addition to the principal sponsorship by the North Atlantic Treaty Organization, the AS1 was co-sponsored by the United States Department of Energy, Office of Health and Environmental Research. Partial financial support was also provided by the following: Abbott Laboratories. USA; Bristol-Meyers Company, USA; Capintec, Inc., Dow USA; Compagnie Oris Industrie, France; Cytogen Corporation, USA; Organon Teknika, NV, Chemical Company, USA; Medi-Physics, Inc., USA; Belgium; Siemens Gammasonics, Inc., USA; and Sorin Biomedica, Italy. Approximately 110 participants representing about fifteen countries attended this two-week meeting. The main objective of this AS1 was to present a comprehensive program of lectures and presentations in the exciting and relatively new area of radiolabeled monoclonal antibodies. The topics that were covered in depth include: 1) Immunochemistry of hybridomas, and the production, purification, and fragmentation of monoclonal antibodies; 2) Production and the chemistry of radionuclides; 3) Radiohalogenation and radiometal labeling techniques; 4) Specificity, affinity, and immunoreactivity considerations; 5) In-vivo pharmacokinetics and other selection criteria; 6) Radiobiology and radiation dosimetry; 7) Optimum instrumentation and imaging techniques; 8) In-vivo radioimmunoscintigraphyand radioimmunotherapyresults; 9) Clinical studies and experience; and 10) Perspectives and directions for future research. Two workshops on "Methods for Determining Immunoreactivity of Radiolabeled Monoclonal Antibodies - Problems and Pitfalls," and "Radiobiological and Dosimetric Considerations for Immunotherapy with Labeled Antibodies" were also scheduled. There were a total of forty-three tutorial and focused scientific presentations (including the latest research data). In addition to these, eight short oral presentations and six poster presentations were included. Each presentation was followed by extensive discussion periods. The unique NATO AS1 format provided ample opportunities for extensive formal and informal interactions and scientific exchanges among the participants. The abstracts are compiled in the order of their presentation. For the short oral and the poster presentations, only the titles and author names appear. The proceedings of this meeting will be published in's hard-cover book format (NATO AS1 Series: A: Life Sciences) by the Plenum Publishing Corporation, 233 Spring Street. New York, N.Y. 10013, during Spring, 1987. Suresh C. Srivastava NATO AS1 Director
RAD10IMMUNOTHEgAP YOFGANGER: HISTOEIGAL PERSPECTIVES AND PRoSPECl'SFOR THE FUTURE. William H. Beierwaltes. University of Michigan, Ann Arbor, Michigan, USA. Our cure of a patient with advanced malignant melanoma 12/7/51 (U Mich Med Bull 20: 284, 1956) with 27 mCi of I-131 tagged to 90 mg of gamma globulin from rabbits immunized with the patient's own whole live cancer cells furnished encouragement to spend the next 35 years trying to furnish an explanation for the cure. 647